FGF21 and metabolic dysfunction-associated steatohepatitis: Medicinal candidates in development for NASH presented in Table E in S1 File (e. g., pioglitazone, vitamin E, obeticholic acid (OCA), cenicriviroc, linagliptin, pegylated Fibroblast Growth Factor 21 (FGF21)) show effects that suggest the possibility of translatable markers and outcomes from the STAMTM model that could be of potential clinical relevance.